Literature DB >> 21653662

Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action.

Aparna Talekar1, Antonello Pessi, Matteo Porotto.   

Abstract

We have previously described heterotypic peptides from parainfluenza virus that potently inhibit Nipah virus in vitro but are not efficacious in vivo. In contrast, our second-generation inhibitors, featuring a cholesterol moiety, are also efficacious in vivo. The difference between in vitro and in vivo results led us to investigate the basis for this discrepancy. Here, we compare the activities of the compounds in standard laboratory cells and in cells relevant to the natural tropism of Nipah virus, i.e., primary neurons, and show that while our first-generation inhibitors are poorly active in primary neurons, the cholesterol-conjugated compounds are highly potent. These results highlight the advantage of evaluating antiviral potency in cells relevant to natural host target tissue.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653662      PMCID: PMC3147962          DOI: 10.1128/JVI.00452-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

Review 1.  Molecular biology of Hendra and Nipah viruses.

Authors:  L Wang; B H Harcourt; M Yu; A Tamin; P A Rota; W J Bellini; B T Eaton
Journal:  Microbes Infect       Date:  2001-04       Impact factor: 2.700

2.  Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.

Authors:  Akihito Yonezawa; Marielle Cavrois; Warner C Greene
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus.

Authors:  Matthew I Bonaparte; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Bruce A Mungall; Kimberly A Bishop; Vidita Choudhry; Dimiter S Dimitrov; Lin-Fa Wang; Bryan T Eaton; Christopher C Broder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-05       Impact factor: 11.205

4.  Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection.

Authors:  M C Georges-Courbot; H Contamin; C Faure; P Loth; S Baize; P Leyssen; J Neyts; V Deubel
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus.

Authors:  Oscar A Negrete; Ernest L Levroney; Hector C Aguilar; Andrea Bertolotti-Ciarlet; Ronen Nazarian; Sara Tajyar; Benhur Lee
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

6.  Clinical features of Nipah virus encephalitis among pig farmers in Malaysia.

Authors:  K J Goh; C T Tan; N K Chew; P S Tan; A Kamarulzaman; S A Sarji; K T Wong; B J Abdullah; K B Chua; S K Lam
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

7.  Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia.

Authors:  K B Chua; K J Goh; K T Wong; A Kamarulzaman; P S Tan; T G Ksiazek; S R Zaki; G Paul; S K Lam; C T Tan
Journal:  Lancet       Date:  1999-10-09       Impact factor: 79.321

8.  Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion.

Authors:  Matteo Porotto; Matthew Murrell; Olga Greengard; Anne Moscona
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.

Authors:  Matteo Porotto; Barry Rockx; Christine C Yokoyama; Aparna Talekar; Ilaria Devito; Laura M Palermo; Jie Liu; Riccardo Cortese; Min Lu; Heinz Feldmann; Antonello Pessi; Anne Moscona
Journal:  PLoS Pathog       Date:  2010-10-28       Impact factor: 6.823

10.  Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus.

Authors:  Oscar A Negrete; Mike C Wolf; Hector C Aguilar; Sven Enterlein; Wei Wang; Elke Mühlberger; Stephen V Su; Andrea Bertolotti-Ciarlet; Ramon Flick; Benhur Lee
Journal:  PLoS Pathog       Date:  2006-02-10       Impact factor: 6.823

View more
  5 in total

1.  Fatal measles virus infection prevented by brain-penetrant fusion inhibitors.

Authors:  Jeremy C Welsch; Aparna Talekar; Cyrille Mathieu; Antonello Pessi; Anne Moscona; Branka Horvat; Matteo Porotto
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

2.  A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity.

Authors:  Antonello Pessi; Annunziata Langella; Elena Capitò; Silvia Ghezzi; Elisa Vicenzi; Guido Poli; Thomas Ketas; Cyrille Mathieu; Riccardo Cortese; Branka Horvat; Anne Moscona; Matteo Porotto
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

3.  Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment.

Authors:  Aparna Talekar; Antonello Pessi; Fraser Glickman; Uttara Sengupta; Thomas Briese; Michael A Whitt; Cyrille Mathieu; Branka Horvat; Anne Moscona; Matteo Porotto
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

Review 4.  Nano-based approach to combat emerging viral (NIPAH virus) infection.

Authors:  Rout George Kerry; Santosh Malik; Yisehak Tsegaye Redda; Sabuj Sahoo; Jayanta Kumar Patra; Sanatan Majhi
Journal:  Nanomedicine       Date:  2019-03-21       Impact factor: 5.307

Review 5.  The role of macropinocytosis in the propagation of protein aggregation associated with neurodegenerative diseases.

Authors:  Rafaa Zeineddine; Justin J Yerbury
Journal:  Front Physiol       Date:  2015-10-16       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.